OptiNose (OPTN) Reaches New 1-Year Low at $8.64

OptiNose Inc (NASDAQ:OPTN) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $8.64 and last traded at $8.72, with a volume of 5101 shares changing hands. The stock had previously closed at $9.10.

OPTN has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $30.00 price target on OptiNose and gave the company a “buy” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $30.00 price target on OptiNose and gave the company a “buy” rating in a report on Tuesday, August 14th. BMO Capital Markets lowered their price target on OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, August 15th. Finally, Zacks Investment Research downgraded OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $28.75.

The firm has a market cap of $375.17 million and a PE ratio of -1.53. The company has a quick ratio of 10.13, a current ratio of 10.44 and a debt-to-equity ratio of 0.51.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11. The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.57 million. As a group, equities analysts predict that OptiNose Inc will post -2.9 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of OPTN. Thompson Davis & CO. Inc. purchased a new stake in OptiNose during the second quarter valued at $105,000. Summit Trail Advisors LLC purchased a new stake in OptiNose during the second quarter valued at $109,000. MetLife Investment Advisors LLC purchased a new stake in OptiNose during the third quarter valued at $157,000. Dynamic Technology Lab Private Ltd purchased a new stake in OptiNose during the third quarter valued at $230,000. Finally, Sio Capital Management LLC purchased a new stake in OptiNose during the third quarter valued at $336,000. Institutional investors own 47.81% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “OptiNose (OPTN) Reaches New 1-Year Low at $8.64” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://transcriptdaily.com/2018/11/27/optinose-optn-reaches-new-1-year-low-at-8-64.html.

About OptiNose (NASDAQ:OPTN)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: Cost of Equity

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply